Hybio Pharmaceutical Co Ltd (300199):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Hybio Pharmaceutical Co Ltd (300199) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8103
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:24
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Hybio Pharmaceutical Co Ltd (Hybio) is a peptide pharmaceutical company that develops and manufactures of polypeptide drugs. The company offers peptide finished dosage products and peptide active pharmaceutical ingredients. Its finished dosage products include desmopressin for injection, terlipressin for injection, sodium ozagrel for injection, oxytocin for injection, and omeprazole sodium for injection, among others. Hybio provides active pharmaceutical ingredients such as abarelix, calcitonin, copaxone, antide, desmopression, alarelin, bivalirudin, desirudin, elecatonin, fertirelin, ganadorelin, histrelin, leuprorelin, vapreotide and haxapeptide. The company conducts synthesis, purification, lyophilization, quality research, formulation study and pilot production of polypeptide drugs. It markets its products in the US, Canada, Italy, India, Germany and Russia. Hybio is headquartered in Shenzhen, China.

Hybio Pharmaceutical Co Ltd (300199) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Hybio Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Hybio Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Hybio Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Hybio Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Hybio Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Hybio Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Hybio Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Private Equity 11
AMW to Sell Shares to Hybio Pharma and YF Capital Led Consortium 11
Licensing Agreements 13
Shenzhen Hybio Pharma Enters into Licensing Agreement with Akorn 13
Hybio Pharma Enters into Licensing Agreement 14
Equity Offering 15
Hybio Pharma Raises USD98 Million in Private Placement of Shares 15
Hybio Pharma to Raise USD71.5 Million in Private Placement of Shares 16
Debt Offering 17
Hybio Pharma to Raise USD157.8 Million in Public Offering of Medium Terms Notes 17
Hybio Pharma Plans to Raise up to USD145.5 Million in Public Offering of Bonds Due 2022 18
Hybio Pharma Plans to Raise up to USD147.5 Million in Public Offering of Notes 19
Acquisition 20
Hybio Pharma to Acquire Pharma Company for USD214.6 Million 20
Hybio Pharmaceutical Co Ltd – Key Competitors 21
Hybio Pharmaceutical Co Ltd – Key Employees 22
Hybio Pharmaceutical Co Ltd – Locations And Subsidiaries 23
Head Office 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
Hybio Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Hybio Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Hybio Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Hybio Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Hybio Pharmaceutical Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Hybio Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Hybio Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
AMW to Sell Shares to Hybio Pharma and YF Capital Led Consortium 11
Shenzhen Hybio Pharma Enters into Licensing Agreement with Akorn 13
Hybio Pharma Enters into Licensing Agreement 14
Hybio Pharma Raises USD98 Million in Private Placement of Shares 15
Hybio Pharma to Raise USD71.5 Million in Private Placement of Shares 16
Hybio Pharma to Raise USD157.8 Million in Public Offering of Medium Terms Notes 17
Hybio Pharma Plans to Raise up to USD145.5 Million in Public Offering of Bonds Due 2022 18
Hybio Pharma Plans to Raise up to USD147.5 Million in Public Offering of Notes 19
Hybio Pharma to Acquire Pharma Company for USD214.6 Million 20
Hybio Pharmaceutical Co Ltd, Key Competitors 21
Hybio Pharmaceutical Co Ltd, Key Employees 22

List of Figures
Hybio Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Hybio Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Hybio Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Hybio Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Hybio Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Hybio Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Hybio Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Hybio Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Hybio Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Hybio Pharmaceutical Co Ltd (300199):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Rafael Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Rafael Pharmaceuticals Inc (Rafael Pharmaceuticals), formerly Cornerstone Pharmaceuticals Inc, is a clinical-stage, metabolic oncology therapeutics company, which focuses to develop and commercialize cancer metabolism based drugs. The company’s lead drug candidate CPI-613 is designed to targ …
  • Cipher Pharmaceuticals Inc (CPH):企業の財務・戦略的SWOT分析
    Summary Cipher Pharmaceuticals Inc (Cipher) is a pharmaceutical company that develops skin care solutions. The company provides products such as actikerall, a topical solution indicated for the treatment of hyperkeratotic actinic keratosis; beteflam, a topical patch used for the treatment of mild to …
  • Custodian & Allied Plc:企業の戦略・SWOT・財務分析
    Custodian & Allied Plc - Strategy, SWOT and Corporate Finance Report Summary Custodian & Allied Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Strat Aero Plc (AERO):企業の財務・戦略的SWOT分析
    Summary Strat Aero Plc (Strat Aero) formally known as Remote Monitored Systems PLC is an aerospace company that offers management systems, training solutions and consultancy services to the Unmanned Aerial Vehicle (UAV) sector. The company’s services include survey and inspection services, surveilla …
  • Terna Energy SA (TENERGY)-エネルギー分野:企業M&A・提携分析
    Summary Terna Energy SA (Terna Energy) a member of the GEK Terna Group, is an independent power producer. It has a presence in the renewable energy project vertical, from site investigation and assessment of available renewable energy potential, to the design, licensing, construction, and the operat …
  • MAMEE-Double Decker (M) Sdn Bhd:企業の戦略的SWOT分析
    MAMEE-Double Decker (M) Sdn Bhd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Mita-Teknik AS:企業の戦略的SWOT分析
    Mita-Teknik AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Zoetis Inc.:企業の戦略・SWOT・財務情報
    Zoetis Inc. - Strategy, SWOT and Corporate Finance Report Summary Zoetis Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Qurient Co Ltd (115180):製薬・医療:M&Aディール及び事業提携情報
    Summary Qurient Co Ltd (Qurient) is a pharmaceutical company that offers development of new drugs for unmet medical needs. The company provides portfolio of pipeline products such as Q301, Q203, Q701, 5LO INH and CDK7 INH, among others. It is developing products for the treatment of atopic dermatiti …
  • SRF Ltd (SRF):企業の財務・戦略的SWOT分析
    SRF Ltd (SRF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Pathfinder Energy Pty Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Pathfinder Energy Pty Ltd (Pathfinder) is an oil and gas company that offers exploration and development of conventional and unconventional oil and gas resources. The company acquires exploration permits and matures prospects using geophysics and geology. It maintains exploration licenses in …
  • GRP Limited (GRPLTD):企業の財務・戦略的SWOT分析
    GRP Limited (GRPLTD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • The Hub Power Co Ltd (HUBC):企業の財務・戦略的SWOT分析
    The Hub Power Co Ltd (HUBC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Trovagene Inc (TROV)-医療機器分野:企業M&A・提携分析
    Summary Trovagene Inc (Trovagene) is a development stage molecular diagnostic company focusing on the development and commercialization of proprietary molecular genetic detection technologies for screening and monitoring cancer and other diseases. Its product portfolio includes liquid biopsy tests t …
  • Country Club Hospitality & Holidays Ltd.:企業の戦略・SWOT・財務分析
    Country Club Hospitality & Holidays Ltd. - Strategy, SWOT and Corporate Finance Report Summary Country Club Hospitality & Holidays Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Theralase Technologies Inc (TLT):製品パイプライン分析
    Summary Theralase Technologies Inc (Theralase) is a medical equipment company that designs, develops and manufactures laser and laser technology for human, companion animal and equine applications. The company offers products such as controller, multiple probe, triple probe, single probe, multiple p …
  • Alibaba Group Holding Ltd (BABA):企業の財務・戦略的SWOT分析
    Alibaba Group Holding Ltd (BABA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Canadian Imperial Bank of Commerce:企業のM&A・事業提携・投資動向
    Canadian Imperial Bank of Commerce - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Canadian Imperial Bank of Commerce Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on m …
  • CJ Corp (001040):企業の財務・戦略的SWOT分析
    CJ Corp (001040) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Toshiba America Medical Systems Inc-医療機器分野:企業M&A・提携分析
    Summary Toshiba America Medical Systems Inc (TAMS), a subsidiary of Toshiba Medical Systems Corp, is a medical device company which markets and distributes the diagnostic imaging systems. The company offers cardiovascular X-ray, computed tomography, angiography, magnetic resonance, ultrasound and x- …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆